Limits of medical treatment in Toc
DOI:
https://doi.org/10.47924/neurotarget2006418Abstract
Limits of medical treatment in Toc
Metrics
References
Greist J. Bandelow B, Hollander E, Marazziti D, Montgomery S, Nutt D, Ocaza A, Swinson R y Zohar J. CNS Spectrum (Suppl I) 2003, 8:7-16.
RTM-II. Recomendaciones terapéuticas en los Trastornos Mentales. Segunda Edición. Masson. 1999.
Dewan MJ y Pies RW. Tratamiento del paciente resistente en psiquiatría. Ars Medica. 2004. Sutherland SM y Krishan KR: «Tratamiento del paciente resistente con trastorno de ansiedad»121-157.
Stein Dan J y Hollander Eric. Tratado de los Trastornos de Ansiedad. Ars Medica. 2004. Goodman Wayne K.:» Farmacoterapia del trastorno obsesivo-compulsivo».
Hohagen F, Winkelmann G, Rasche-Ruchle H,et al:Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Reslts of a multicentre study. Br. J Psychiatry Suppl(35):71- 78,1998.
Jenike MA:Drug treatment of obsessive-compulsive disorder, in Obsessive-Compulsive Disorders: Practical Management, 3rd Edition. St. Louis,MO,CV Mosby,1998,pp469-532.
Grossman R, Hollander E: Treatment of obsessive-complusive disorder with venlafaxine. Am.J. Psychiatry. 153:576-577,1996.
Goodman WK, Ward HE, Murphy TK: Biologic approaches to treatment refractory obsessive-compulsive disorder. Psychiatry Annals 28:641- 649,1998.
Mrazziti D, Gemignani A, Dell Osso L: Trazondone augmentation in OCD: a case series report. CNS.Spectrums 4:48-49,1999.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2006 Sergio Zamora Delgado
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
